As reported by The Manila Times, MediciNova has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a new patent application involving its investigational drug ibudilast (MN-166). The patent pertains to the use of this agent alongside anti–PD-1 immune checkpoint inhibitors in the treatment of glioblastoma, an aggressive and difficult-to-treat brain tumor.
Strengthening Strategy in Combination Oncology
The allowance represents an important step in reinforcing the company’s intellectual property portfolio around MN-166, particularly in oncology. The claims extend beyond the basic drug pairing and include a wide range of therapeutic variables such as dosing schedules, administration routes, and duration of therapy. This breadth is designed to support flexible clinical development strategies as MediciNova explores combination regimens.
Company leadership emphasized that the decision underscores confidence in ibudilast as a potential component of multi-agent therapy approaches. According to MediciNova’s chief medical officer, the patent supports ongoing efforts to evaluate rational combinations aimed at improving outcomes in glioblastoma, where treatment options remain limited and prognosis is poor.
Patent Scope and Timeline
Once formally granted, the patent is expected to remain in force until at least September 2042. Its coverage includes combinations of ibudilast with various anti–PD-1 antibodies, reflecting the growing role of immune checkpoint inhibition in oncology. By encompassing multiple treatment parameters, the patent may offer long-term protection for diverse clinical applications of the therapy.
About Ibudilast (MN-166)
Ibudilast is an orally administered small molecule with anti-inflammatory and neuroprotective properties. It acts by inhibiting phosphodiesterase-4 and suppressing pro-inflammatory mediators, including macrophage migration inhibitory factor. The compound is in advanced clinical development for several neurologic conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis, and degenerative cervical myelopathy.
In addition to its neurological indications, MN-166 is being explored in oncology and other areas such as chemotherapy-induced peripheral neuropathy, Long COVID, and substance use disorders. Its potential role in glioblastoma reflects broader interest in targeting inflammation and the tumor microenvironment as part of combination treatment strategies.
Outlook
The newly allowed patent may provide MediciNova with strategic leverage as it continues to develop MN-166 in combination with immunotherapies. With glioblastoma still associated with high unmet medical need, advances in therapeutic approaches—including combination regimens—are considered a key area of innovation.
